NCT06245772 (CARBUR) is a clinical trial in Upper Limb Injury, sponsored by Ipsen.

Who is sponsoring NCT06245772?

NCT06245772 is sponsored by Ipsen.

What condition does NCT06245772 study?

NCT06245772 studies Upper Limb Injury.

Is NCT06245772 still recruiting?

NCT06245772 is currently active, enrolled. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT06245772: CARBUR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity

Active, enrolled Last updated 4 March 2026

What this trial tests

trial in Upper Limb Injury in 113 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 November 2023

Primary endpoint
28 February 2026

28 February 2027

Quick facts

Lead sponsor	Ipsen
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	113
Start date	16 November 2023
Primary completion	28 February 2026
Estimated completion	28 February 2027
Sites	27 locations across France

Conditions studied

Upper Limb Injury — all drugs for Upper Limb Injury →

Sponsor

Ipsen — full company profile →

Who can join

18 and older, any sex, with Upper Limb Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability and other health care measures in patients affected with ULS due to acquired brain injuries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Upper Limb Injury

Currently open trials in the same condition.

NCT06685094 — Translation and Validation of the Upper and Lower Limbs, Pain, Autonomy and Quality of Life Scales in Albanian · recruiting

Other Ipsen trials

Trials by the same sponsor.

NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06245772 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ipsen
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing